Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ≥50% (vol 14, pg 1, 2022)

被引：0
|
作者：
Freemantle, N.
Xu, Y.
Wilson, F. R.
机构：
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2022年 / 14卷
关键词：
D O I：
10.1177/17588359221127078
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Meta-Analysis of PD-L1 Expression as a Biomarker of PD-1 Blockade in Advanced Non-Small Cell Lung Cancer
    Man, J.
    Gebski, V.
    Mulvey, A.
    Hui, R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2001 - S2002
  • [42] Non-small cell Lung Cancer Atezolizumab is now also approved for First-Line Monotherapy for high PD-L1 Expression
    Vetter, Christine
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [43] A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
    Fu, Jie
    Yan, Yi-Dan
    Wan, Xu
    Sun, Xiao-Fan
    Ma, Xiu-Mei
    Su, Ying-Jie
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [44] Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
    Li, Dan-Ni
    Lu, Wen-Qing
    Yang, Bo-Wen
    Zhang, Ling-Yun
    Jin, Bo
    Wang, Shuo
    Che, Xiao-Fang
    Li, Ce
    Liu, Yun-Peng
    Qu, Xiu-Juan
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [45] Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
    Sezer, Ahmet
    Kilickap, Saadettin
    Gumus, Mahmut
    Bondarenko, Igor
    Ozguroglu, Mustafa
    Gogishvili, Miranda
    Turk, Haci M.
    Cicin, Irfan
    Bentsion, Dmitry
    Gladkov, Oleg
    Clingan, Philip
    Sriuranpong, Virote
    Rizvi, Naiyer
    Gao, Bo
    Li, Siyu
    Lee, Sue
    McGuire, Kristina
    Chen, Chieh-, I
    Makharadze, Tamta
    Paydas, Semra
    Nechaeva, Marina
    Seebach, Frank
    Weinreich, David M.
    Yancopoulos, George D.
    Gullo, Giuseppe
    Lowy, Israel
    Rietschel, Petra
    LANCET, 2021, 397 (10274): : 592 - 604
  • [46] Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis
    Zhang, Binbin
    Liu, Yi
    Zhou, Sijing
    Jiang, Huihui
    Zhu, Ke
    Wang, Ran
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 80
  • [47] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1817 - 1818
  • [48] Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
    Shen, Xuxia
    Li, Yuan
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1817 - 1818
  • [49] Clinical benefit of anti PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment in advanced non-small cell lung cancer: A meta-analysis
    Landre, T.
    Des Guetz, G.
    Vergnenegre, A.
    Chouaid, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [50] Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: network meta-analysis
    Molife, Cliff
    Brnabic, Alan
    Stefaniak, Victoria J.
    Belger, Mark A.
    Gruver, Kristi
    Chen, Jing, V
    Souri, Saman
    Blumenschein, George R.
    IMMUNOTHERAPY, 2023, 15 (04) : 293 - 309
12345